dc.contributor.author | Alehagen, Urban | |
dc.contributor.author | Johansson, Peter | |
dc.contributor.author | Aaseth, Jan | |
dc.contributor.author | Alexander, Jan | |
dc.contributor.author | Brismar, Kerstin | |
dc.date.accessioned | 2018-04-04T13:12:41Z | |
dc.date.available | 2018-04-04T13:12:41Z | |
dc.date.created | 2017-07-10T10:53:02Z | |
dc.date.issued | 2017 | |
dc.identifier.citation | PLoS ONE. 2017, 12 (6), . | nb_NO |
dc.identifier.issn | 1932-6203 | |
dc.identifier.uri | http://hdl.handle.net/11250/2492632 | |
dc.description.abstract | Abstract
Background
Insulin-like growth factor-1(IGF-1) has a multitude of effects besides cell growth and metabolism.
Reports also indicate anti-inflammatory and antioxidative effects. The concentrations
of IGF-1 decrease with age and during inflammation. As selenium and coenzyme Q10 are
involved in both the antioxidative defense and the inflammatory response, the present study
aimed to examine the effects of supplementation with selenium and coenzyme Q10 on concentrations
of IGF-1 and its binding protein IGFBP-1 in a population showing reduced cardiovascular
mortality following such supplementation.
Methods
215 elderly individuals were included and given the intervention for four years. A clinical
examination was performed and blood samples were taken at the start and after 48 months.
Evaluations of IGF-1, the age adjusted IGF-1 SD score and IGFBP-1 were performed using
group mean values, and repeated measures of variance.
Findings
After supplementation with selenium and coenzyme Q10, applying group mean evaluations,
significantly higher IGF-1 and IGF-1 SD scores could be seen in the active treatment group,
whereas a decrease in concentration could be seen of the same biomarkers in the placebo
group.
Applying the repeated measures of variance evaluations, the same significant increase
in concentrations of IGF-1 (F = 68; P>0.0001), IGF-1 SD score (F = 29; P<0.0001) and
of IGFBP-1 (F = 6.88; P = 0.009) could be seen, indicating the effect of selenium and coenzyme
Q10 also on the expression of IGF-1 as one of the mechanistic effects of the
intervention.
Conclusion
Supplementation with selenium and coenzyme Q10 over four years resulted in increased
levels of IGF-1 and the postprandial IGFBP-1, and an increase in the age-corrected IGF-1
SD score, compared with placebo. The effects could be part of the mechanistic explanation
behind the surprisingly positive clinical effects on cardiovascular morbidity and mortality
reported earlier. However, as the effects of IGF-1 are complex, more research on the result
of intervention with selenium and coenzyme Q10 is needed. | nb_NO |
dc.description.sponsorship | Funding: Part of the analysis costs was supported by grants from Family Erling-Persson Foundation, Medical Research Council, Pharma Nord Aps, Denmark, the County Council ofOÈ stergoÈtland, LinkoÈping University. The selenium tablets and coenzyme Q10 capsules were kindly donated by Pharma Nord Aps. The funding organizations had no role in the design, management, analysis, interpretation of the data, preparation, review or approval of the manuscript. | nb_NO |
dc.language.iso | eng | nb_NO |
dc.relation.uri | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469470/pdf/pone.0178614.pdf | |
dc.rights | Navngivelse-Ikkekommersiell-DelPåSammeVilkår 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/deed.no | * |
dc.title | Increase in insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 1 after supplementation with selenium and coenzyme Q10. A prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens | nb_NO |
dc.type | Peer reviewed | en |
dc.type | Journal article | en |
dc.description.version | publishedVersion | nb_NO |
dc.rights.holder | Competing interests: The authors received donations (study tablets/capsules or placebo) and funding (part of the echocardiographical costs) from Pharma Nord Aps. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials. | nb_NO |
dc.source.pagenumber | 17 | nb_NO |
dc.source.volume | 12 | nb_NO |
dc.source.journal | PLoS ONE | nb_NO |
dc.source.issue | 6 | nb_NO |
dc.identifier.doi | 10.1371/journal. pone.0178614 | |
dc.identifier.cristin | 1481683 | |
cristin.unitcode | 1991,0,0,0 | |
cristin.unitname | Sykehuset Innlandet HF | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |